Ventyx Biosciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Ventyx Biosciences' Senior VP of Finance, Roy Gonzales, disposed of all his common stock and stock options following the company's merger with Eli Lilly and Company.
Director Somu Subramaniam reports disposition of Ventyx Biosciences shares and options following its acquisition by Eli Lilly for $14.00 per share.
A Ventyx Biosciences director's stock options were either cashed out or cancelled following the company's acquisition by Eli Lilly and Company.
Ventyx Biosciences Chief Operating Officer Matthew Richard Moore's stock options were cancelled and converted to cash following the company's merger with Eli Lilly and Company.
Ventyx Biosciences director Onaiza Cadoret-Manier's stock options were cancelled and converted to cash or no consideration following the acquisition by Eli Lilly and Company.
Ventyx Biosciences Director Allison Hulme's stock options were cancelled as part of the company's acquisition by Eli Lilly and Company, with some converted to cash and others for no consideration.
Ventyx Biosciences Director Sheila Gujrathi reports the disposition of common stock and cancellation of stock options following the company's acquisition by Eli Lilly and Company.
Ventyx Biosciences, Inc. CEO Raju Mohan converted all common stock, restricted stock units, and eligible stock options into cash following the merger with Eli Lilly and Company.
Ventyx Biosciences Chief Medical Officer Mark S. Forman disposed of all common stock and stock options following the company's merger with Eli Lilly and Company, receiving cash consideration.
Ventyx Biosciences CEO Raju Mohan sold 47,345 shares of common stock to cover tax withholding obligations after 116,668 restricted stock units vested.
Ventyx Biosciences' Chief Scientific Officer, John Nuss, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.
Ventyx Biosciences' Chief Medical Officer, Mark S. Forman, acquired 3,000 shares of common stock through the company's Employee Stock Purchase Plan.
Ventyx Biosciences' Senior VP of Finance, Roy Gonzales, acquired 1,767 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price.
Ventyx Biosciences, Inc. director Onaiza Cadoret-Manier was granted 40,000 stock options with an exercise price of $2.25, aligning her incentives with shareholder value.
Ventyx Biosciences, Inc. Director Allison Hulme was granted 40,000 stock options with an exercise price of $2.25, aligning her interests with the company's long-term performance.
Ventyx Biosciences, Inc. director Somu Subramaniam was granted 40,000 stock options with an exercise price of $2.25, vesting based on continued service.
Ventyx Biosciences, Inc. Director William Richard White was granted 40,000 stock options with an exercise price of $2.25, as disclosed in a recent SEC Form 4 filing.
Ventyx Biosciences, Inc. Director Sheila Gujrathi was granted 40,000 stock options with an exercise price of $2.25, aligning her interests with shareholder value.
Roy Gonzales, Senior VP of Finance at Ventyx Biosciences, reports the acquisition of 1,750 shares of common stock through the company's Employee Stock Purchase Plan at a price of $1.03 per share.
Form 4: Ventyx Biosciences Chief Medical Officer Acquires 3,000 Shares Through Employee Stock Purchase Plan
Mark S. Forman, Chief Medical Officer of Ventyx Biosciences, acquired 3,000 shares of common stock through the company's Employee Stock Purchase Plan at a price of $1.03 per share.
John Nuss, Chief Scientific Officer of Ventyx Biosciences, sold 1,887 shares of common stock on April 2, 2025, to satisfy tax withholding obligations related to vesting restricted stock units.
CEO Raju Mohan reports the vesting of restricted stock units resulting in the acquisition of 11,844 shares of Ventyx Biosciences common stock.
John Nuss, Chief Scientific Officer of Ventyx Biosciences, reports the vesting and disposal of restricted stock units.
Somu Subramaniam, a director of Ventyx Biosciences, reports the distribution of shares from NSV Investments I, L.P. to its limited partners.
Director Somu Subramaniam reports a distribution of Ventyx Biosciences shares from NSV Investments I, L.P. to its limited partners.
John Nuss, Chief Scientific Officer of Ventyx Biosciences, acquired stock options for 415,104 shares of common stock on January 2, 2025.
Ventyx Biosciences CEO, Raju Mohan, was granted 700,000 stock options on January 2, 2025, which vest monthly over four years.
Ventyx Biosciences' Chief Operating Officer, Matthew Richard Moore, was granted 145,000 stock options on January 2, 2025.
Roy Gonzales, Senior VP of Finance at Ventyx Biosciences, acquired stock options for 126,700 shares on January 2, 2025, according to a recent SEC filing.
Ventyx Biosciences' Chief Medical Officer, Mark S. Forman, was granted 85,000 stock options on January 2, 2025, according to a recent SEC filing.